Abstract: FR-PO234
Cannabis Use and Its Association with eGFR Decline in Advanced CKD Patients Transitioning to ESRD
Session Information
- CKD: Clinical, Outcomes, Trials - II
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Potukuchi, Praveen Kumar, University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Sumida, Keiichi, Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, KANAGAWA, Japan
- Molnar, Miklos Zsolt, University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Gaipov, Abduzhappar, University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Park, Frank, University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Kaplan, Cameron M., University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Moradi, Hamid, University of California Irvine, School of Medicine, Orange, California, United States
- Thomas, Fridtjof, University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Gatwood, Justin, University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Streja, Elani, Harold Simmons Center for Kidney Disease Research and Epidemiology, Orange, California, United States
- Kalantar-Zadeh, Kamyar, University of California Irvine, School of Medicine, Orange, California, United States
- Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States
Background
The renal safety of cannabis use in patients with advanced CKD is unknown.
Methods
We examined 6,788 US veterans who transitioned to dialysis during 2007-2014 and had undergone urine toxicology tests within a year before the dialysis initiation. We compared patients whose toxicology tests were positive for cannabis alone (primary exposure group, PEG, N=195) with those whose tests were negative (negative control group, NCG, N=3,266). We estimated slopes of eGFR and the effect of inter-individual cannabis use on intraindividual slopes in multilevel mixed-effects models with random intercepts and slopes adjusted for sociodemographics, comorbidities, medications, and vital signs.
Results
The mean (SD) age of the cohort was 60.5 (9.6) years; 97% were male, 46 % were African American and 72% were diabetic. The median (IQR) eGFR slope was -10.9 (-17.2, -6.1) ml/min/1.73m2/year. Cannabis use was associated with significantly steeper eGFR slopes in the unadjusted model (Figure 1, estimated slope in the PEG compared to NCG group (95% CI) -3.55 (-6.58, -0.51) ml/min/1.73m2/year, P=0.02) However, after multivariable adjustments cannabis use was not associated with steeper slopes.
Conclusion
Cannabis use is not associated with more rapid loss of kidney function in patients with advanced CKD.
Funding
- NIDDK Support